Peripheral blood stem cell collection in multiple myeloma: A retrospective analysis of 6 years leukapheresis activity in 109 patients treated at the Istituto Nazionale dei Tumori of Milan
- 1 January 2009
- journal article
- research article
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 24 (4) , 134-140
Abstract
Double autologous stem cell transplantation is the standard treatment in newly diagnosed multiple myeloma (MM) patients younger than 65 years; therefore, optimization of leukapheresis is crucial. We performed a retrospective analysis of 297 leukaphereses comparing semiautomated (V4.7 in 20% of collections) versus automated (V6.0 in 80%) Caridian (COBE) Spectra versions and analyzing the influence of M-protein on the outcome. Both methods gave comparable collection efficiencies (CE%) (53.4% vs. 55.7% in V6.0 and V4.7, respectively) with similar leukapheresis time and processed volume. Harvest volume was higher in V4.7 (P < 0.0001) with similar contamination of red blood cells (RBCs) (P = 0.77) and platelets (P = 0.09) when compared with V6.0. In patients with higher peripheral white blood cells (WBCs), V6.0 with adjusted harvest volume (+ CE% (P = 0.39) and better enrichment of nucleated cells (P < 0.0,002) but higher RBCs (P < 0.0,001) and platelets contamination (P = 0.001), when compared with a larger cycle volume in patients with lower WBCs. In hard to mobilize patients, CD34+ CE% was significantly more efficient with V4.7 than V6.0 (P < 0.0,001). CD34+ CE% was unaffected by serologic M-protein, but platelet CE% was higher in the absence of M-protein (P = 0.0,003), without any reduction in peripheral patients platelets. We, therefore, conclude that in the setting of MM patients with a high WBCs count and/or low percentage of peripheral CD34+ cells, collections with V4.7 or adjusted cycle volume V6.0 gave comparable result in CD34+ CE%. RBCs and platelets contamination is higher if low cycle volume is chosen. In hard to mobilize patients, V4.7 is advisable. J. Clin. Apheresis, 2009.Keywords
This publication has 19 references indexed in Scilit:
- The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapiesBone Marrow Transplantation, 2009
- Multiple myeloma patients receiving large volume leukapheresis efficiently yield enough CD34+ cells to allow double transplantsJournal of Clinical Apheresis, 2009
- Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous TransplantationTransplantation and Cellular Therapy, 2008
- Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: practical issuesEuropean Journal of Haematology, 2008
- Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical StudyJournal of Clinical Oncology, 2007
- Evolving Role of Stem Cell Transplantation in Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2005
- Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizersBlood, 2004
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaNew England Journal of Medicine, 2003
- Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelinesCytometry, 1998
- Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin’s lymphoma patients after combination chemotherapy and G-CSFBone Marrow Transplantation, 1997